Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MENS, unsubscribe in one click. Privacy
MENS holds $1.2M in cash and short-term investments and burns about $760,250/quarter from operations, an estimated runway of 4.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 55 · Elevated
We concluded that there is substantial doubt about our ability to continue as a going concern for a period of one year from the date that the unaudited interim consolidated financial statements included in this registration statement were issued.20-F, May 2026
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MENS files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MENS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →